alzheon, Author at Alzheon | Preserving Future Memories - Page 2 of 20

About alzheon

This author has not yet filled in any details.
So far alzheon has created 200 blog entries.

11 Jun, 2024

Breakthroughs in Alzheimer Research Pave Way for New Era of Treatment: Martin Tolar, MD, PhD

alzheon2024-06-26T14:05:46-04:00June 11th, 2024|

30 Apr, 2024

Alzheon Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer’s Disease

alzheon2024-08-26T10:57:45-04:00April 30th, 2024|

8 Apr, 2024

Alzheon Announces that United States Federal Circuit Affirmed Decision of U.S. Patent Office Invalidating Risen (Suzhou) Pharmaceutical Technology Co., Ltd.’s Patent on Isotopically Enriched Forms of ALZ-801/Valiltramiprosate

alzheon2024-08-26T11:00:41-04:00April 8th, 2024|

2 Apr, 2024

Beginning a New Era of Precision Alzheimer’s Therapeutics

alzheon2024-06-03T14:44:54-04:00April 2nd, 2024|Tags: Inside Precision Medicine|

26 Mar, 2024

Peer-Reviewed Scientific Publication Proposes Unifying Single Toxin Theory of Brain Neurodegeneration that Identifies New Drug Targets and Treatments for Alzheimer’s Disease and Other Neurodegenerative Disorders

alzheon2024-08-12T10:16:59-04:00March 26th, 2024|

27 Feb, 2024

The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention

alzheon2024-06-19T16:17:21-04:00February 27th, 2024|

27 Feb, 2024

Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

alzheon2024-08-12T09:58:01-04:00February 27th, 2024|

11 Jan, 2024

Newsweek Investment Report: Interview with Dr. Martin Tolar, President & CEO of Alzheon, Inc. January 2024

alzheon2024-06-03T14:42:41-04:00January 11th, 2024|Tags: Newsweek|

3 Jan, 2024

Alzheon CEO Dr. Martin Tolar to Present ALZ-801/Valiltramiprosate Investigational Oral Alzheimer’s Treatment Program at Nobel Forum at Karolinska Institute in Stockholm, Sweden

alzheon2024-08-05T19:40:59-04:00January 3rd, 2024|

3 Jan, 2024

Alzheon CEO Dr. Martin Tolar Awarded Eliška and Zdeněk Strmiska Award from Alzheimer’s Foundation for Significant Contribution Towards Research and Treatment of Alzheimer’s Disease, and Donated Cash Prize to INDRC Institute

alzheon2024-08-05T19:26:13-04:00January 3rd, 2024|